Market Overview

The Global Inflammatory Bowel Disease Treatment Market size was valued at USD 26.66 billion in 2023 and is projected to grow from USD 29.68 billion in 2024 to USD 44.19 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period (2024-2032).

Inflammatory Bowel Disease (IBD), which encompasses both Crohn's disease (CD) and ulcerative colitis (UC), is a condition that affects people worldwide. In early industrialized North America, Europe, and Oceania, the incidence increased significantly throughout the second half of the 20th century. The incidence of IBD levelled off in many Western regions at the start of the twenty-first century. However, Scandinavia has reported some of the highest incidence rates of IBD, and the incidence of IBD with a childhood onset continues to rise for unknown causes. Elucidating age and geographic variations in the incidence of IBD over time may provide clues about the environmental factors that contribute to the aetiology of this disease.

• According to estimates, in 2023 there will be 29.9 cases of IBD per 100,000 people (95% PI 28.3–31.5) nationwide. Incidence of IBD is predicted to be 31.2 per 100,000 (95% PI 28.1–34.3) in 2035 with a consistent AAPC of 0.36% (95% CI −0.05 to 0.72).
• In the world, there were 6·8 million (95% confidence ranges 6·4-7·3) cases of IBD, according to this study. Following methodological adjustments, the number has sharply decreased to 4.9 million in the 2019 GBD research.

Market growth will be driven by the upcoming product launches and a strong pipeline of new products. For instance, AbbVie Inc. received approval from the European Commission (EC) in April 2023 to use Rinvoq (upadacitinib) to treat adult patients with moderate to severe Crohn's disease. The objectives of the current therapy are long-term remission, reduced inflammation, and reduced risk of complications.

Additionally, working in close collaboration with pharmaceutical companies, hospitals and other healthcare facilities initiate and successfully conduct clinical trials and ensure patient safety in the process. Such projects will enhance research and bring a new treatment for IBD. Providing new drugs in Crohn's disease as well as ulcerative colitis, and embracing recent technological advances such as the use of AI in drug development are high on the agenda for all top players in the IBD treatment market. For instance, in December 2023, Insilco Medicine administered its first patients with its investigational IBD drug candidate, ISM5411, designed using generative AI. Top companies and technology leaders are also collaborating to leverage each other's technologies and expertise to build best-in-class practices and to gain ground. For instance, Israel-based tech start up CytoReason announced in May 2021 that it was in partnership with Furring Pharmaceuticals. It would employ AI technology to create innovative therapies for IBD and speed up the drug development process.

Key Findings:

• S. prevalence of inflammatory bowel disease (IBD) is estimated between 2.4 and 3.1 million, with differing burden across groups.
• IBD prevalence and health care costs are rising.
• In 2018, the total annual U.S. health care costs for IBD were about $8.5 billion.
• Biologic prescription drugs have shifted the patterns of cost and service use.

Market Dynamics - Market Drivers

Increasing Prevalence of Inflammatory Bowel Disease (IBD)

A rising incidence of inflammatory bowel disease, which includes both Crohn's disease and ulcerative colitis, is one of the major growth drivers in the Global IBD Treatment Market. Some of these factors include genetic predispositions and environmental influences and lifestyle alterations such as diet and stress. Since more people are being diagnosed with this condition, the demand for treatment options also increases, involving biologics, immunosuppressant, and new therapies. Increasing emphasis on early diagnosis and treatment planning is augmenting market growth as increasing patients have been demanding treatment.

Advancements in Treatment Options

Innovation in the development of new therapies, especially biologics and biosimilars, has greatly revolutionized IBD treatment. New drugs specifically aimed at certain pathways in the inflammatory process are providing a more effective and targeted therapy with better patient outcomes. On-going research and clinical trials are bringing new therapeutics into the market, giving healthcare professionals more choices for their patients. Personalized medicine further drives up the efficiency of treatment; thus, the market increases with a growing demand by patients for targeted therapies that specifically suit their condition.

Market Opportunities

Growing Investment in Research and Development

Investment is also significant in terms of R&D, targeted to produce novel therapies and enhance available treatments of IBD. In parallel, pharmaceutical companies are beginning to associate more frequently with research centres in finding new active molecules and treatment modalities. This investment may find novel solutions that lead to breaking barriers in the treatment of IBD. With the new product arriving in the market to meet the unmet medical needs of such patients, the global IBD treatment market would also enjoy the benefits.

Expansion Into Emerging Markets

The emerging economies have huge growth opportunities for the Global IBD Treatment Market. Increasing awareness of IBD and the improving healthcare infrastructure in these regions make more patients available for diagnostic and treatment options. This growth in the market is backed by increasing disposable income and changing lifestyles in the respective countries, thus increasing the demand for advanced medical therapies. Pharmaceutical companies can leverage these opportunities by creating operations in those countries and modifying their strategies to suit local market needs.

Market Restraining Factors

High Cost of Treatment

Advanced IBD therapies, and biologics in specific, cost a lot that hinders growth in the market. Due to this fact, patients are deterred from pursuing these treatments for financial reasons, thus creating under-treatment or poor compliance with the prescribed drug. Differences in insurance coverage and co-payments affect access to treatments and create fewer patients eligible to be treated under advanced therapies. This high cost creates difficulty in market penetration, especially within price-sensitive areas.

Regulatory Challenges

Regulatory environment is another barrier to entry for companies in the Global IBD Treatment Market. The lengthy process for drug approval delays the product launch and increases development costs. Regulatory agencies are known to require massive clinical trial data that ensures drugs are safe and effective. These are barriers for small companies or companies that bring in innovative therapies. They may hinder entry into the market and slow the pace of innovation in the IBD treatment landscape.

Segmentation Analysis

The market scope is segmented because of by Route of Administration, by Disease Indication, by Drug Class, by Distribution Channel.

By Route of Administration

Based on the Route of Administration of the market is segmented into Oral, Injectable.

The two segments of the market are oral and injectable globally. More people receiving treatment for Crohn's disease and ulcerative colitis with biologics as well as the increasing numbers of product approvals for the drugs will keep the largest share of the market in the category of injectable. AbbVie Inc., for instance, reported in February 2021 that HUMIRA had gained FDA approval for the treatment of young patients suffering from moderate to highly active ulcerative colitis. HUMIRA is administered through subcutaneous injections. Hence, the market for injectable is growing due to an increase in demand for biologics in treating IBD. The simplicity of the self-administration of oral medications, especially for cases of mild to moderate ulcerative colitis and Crohn's disease, as well as access to oral medications to treat IBD, would contribute to the expansion of the oral market.

By Disease Indication

Based on the Disease Indication of the market is segmented into Ulcerative Colitis, Crohn's Disease.

The market is bifurcated into ulcerative colitis and Crohn's disease on the basis of disease indication. Through the course of the projection period, the market share for treatments against inflammatory bowel disease will be considerable in the sector of Crohn's disease. The increase in cases of Crohn's disease and the people under its treatment globally are held accountable for the growth of this segment. As stated in the Deutsches Ärzteblatt, for instance, there are between 100 to 200 cases of Crohn's disease per 100,000 individuals in Germany.

The increasing number of drugs approved by regulatory bodies to treat ulcerative colitis and the increasing global treatment rate of the condition are the reasons for the segment's rise.

Key Findings:

• In October 2023, the FDA approved Pfizer Inc.'s VELSIPITY (Etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, for individuals with moderately to severely active ulcerative colitis (UC).
• In March 2022, RINVOQ (Upadacitinib) has been approved by the FDA to treat adults with moderate to highly active ulcerative colitis, according to a statement released by AbbVie.

By Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America accounted for the highest share in 2023 with a size estimated at USD 10.93 billion due to favourable reimbursement policies, the growing prevalence of ulcerative colitis and Crohn's disease in the United States and Canada, and growing use of biologics in treating these diseases. The NCBI, for instance estimates that in 2021, the prevalence of inflammatory bowel disease in Canada will be greater than 0.75%.

In a similar fashion, regional expansion is expected to be driven by strategic initiatives by major corporations. A definitive agreement by Merck and Prometheus Biosciences, Inc. was executed in April 2023. Pursuant to the deal, Merck paid in cash USD 200.00 for each share of Prometheus, aggregating to an equity value of approximately USD 10.8 billion. The company's immunology pipeline will be enhanced by this project.

Europe ranked second in terms of market share in 2021. One of the main factors driving the growth of the market is the increasing number of patients receiving treatment for the disease in the region. Several disease-related therapy options are some of the factors driving the growth of the European market. Because more people in the region are becoming aware of Crohn's disease and ulcerative colitis and because more prescription medications are being approved to treat these conditions, the Asia Pacific market is expected to grow at a faster rate throughout the projection period. For example, in Japan, EA Pharma Co., Ltd. was granted approval in March 2022 to use CAROGRA as a treatment for ulcerative colitis.

The market in Latin America is growing due to regionally increasing awareness of Crohn's disease and ulcerative colitis, increased health spending, and the increasing prevalence of these diseases. Market in the Middle East and Africa due to lifestyle changes and due to the increasing prevalence of smoking which increases disease risk, is expected to grow at a substantial pace over the course of the forecast period. In addition, the market in the region is growing due to the increased number of individuals requiring these treatments.

Prevalence in the United States:

Depending on the data source, current estimates of IBD in the United States vary considerably:

• Ranging from 2.4–2.8 million IBD patients based on administrative claims data.
• Up to 3.1 million adults with the disease based on national survey data.

List of Companies Profiled

• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Biogen
• Novartis AG
• Lilly
• UCB S.A.
• CELLTRION INC.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc

Key Industry Developments

• In May 2024, Johnson and Johnson Services Inc., announced the first phase 3 results for Tremfya’s Crohn’s disease program. The data from phase 3 trial demonstrated that Tremfya is superior to Stelara in all the endoscopic patients in the trial pool.
• In April 2024, Takeda Pharmaceutical Company Limited received FDA approval for subcutaneous administration of Entyvio post-induction therapy with IV Entyvio. The drugs are used to treat patients with severely active Crohn’s Disease.
• In October 2023, Johnson & Johnson Services, Inc. announced the data from a phase 3 clinical trial of Tremfya (guselkumab), studying the safety and efficacy of the drug for active ulcerative colitis. The study showed a 77% overall clinical response rate and early symptom improvement in UC patients.
• In June 2023, Lilly's Omvoh (mirikizumab) received market authorization from UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of ulcerative colitis.
• In February 2023, AbbVie announced that the UK's MHRA approved RINVOQ, a JAK inhibitor, for treating patients with moderate to severe Crohn's disease who had an inadequate response to conventional therapy.
• In January 2023, Inotrem, a clinical-stage biotechnology company, received funding from the Crohn's & Colitis Foundation to help develop novel therapeutic approaches in Crohn's disease and ulcerative colitis.

Report Coverage

The report will cover the qualitative and quantitative data on the global Inflammatory Bowel Disease Treatment Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Inflammatory Bowel Disease Treatment market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Inflammatory Bowel Disease Treatment . The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Inflammatory Bowel Disease Treatment companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Inflammatory Bowel Disease Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Inflammatory Bowel Disease Treatment Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Inflammatory Bowel Disease Treatment Market valued?
• Which region has the largest share in 2024 for the global Inflammatory Bowel Disease Treatment Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of the Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Inflammatory Bowel Disease Treatment Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: